Trial Profile
Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin: a Multicenter, Prospective, Observational Study in a Real World Setting
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2021
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 21 Jun 2020 Interim results presented at the 25th Congress of the European Haematology Association
- 25 Oct 2019 Status changed from not yet recruiting to recruiting.
- 21 Mar 2018 Planned initiation date changed from 1 Mar 2018 to 31 Mar 2018.